Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting.

Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting.

To assess incidence charges (IRs) of VTE in patients with rheumatoid arthritis (RA) on completely different DMARDs and DMARD switchers.Adults with RA on a DMARD between 2007 and 2017 have been studied in a US claims database.

Conventional synthetic DMARD (csDMARD) customers, first biologic/targeted synthetic DMARD (b/tsDMARD) customers and b/tsDMARD switchers (from a b/tsDMARD to a different b/tsDMARD) have been adopted for inpatient VTE (pulmonary embolism (PE)/deep vein thrombosis (DVT)).

Crude and adjusted IR and 95% CIs of VTE have been estimated. HRs for VTE have been estimated through Cox regression. VTE danger was additionally evaluated by quantity of switches between b/tsDMARDs and in patients and not using a VTE historical past.

Results

The age and intercourse standardised IR (95% CI) of VTE (per 100 person-years) was 0.86 (0.70 to 1.03), 0.60 (0.52 to 0.68) and 0.58 (0.51 to 0.65) for b/tsDMARD switchers, first b/tsDMARD customers and csDMARD customers, respectively. After adjustment, b/tsDMARD switchers had an elevated danger of VTE, in contrast with csDMARD customers, HRadj (95% CI) being 1.36 (1.16 to 1.58), 1.36 (1.13 to 1.63) and 1.47 (1.18 to 1.83) for VTE, DVT and PE, respectively.

Compared with first b/tsDMARD customers, the HRadj (95% CI) for VTE was 1.35 (1.15 to 1.60) for first b/tsDMARD switchers and 1.48 (1.19 to 1.85) for second b/tsDMARD switchers.In RA, b/tsDMARD switchers have the next VTE danger in contrast with csDMARD customers and first b/tsDMARD customers.

Polyclonal Goat anti-GST μ-form

GST-ANTI-2 50 uL
EUR 336

Polyclonal Goat anti-GST p-form

GST-ANTI-3 50 uL
EUR 336

Anti-Anti-SEPT6 antibody antibody

STJ11100949 100 µl
EUR 332.4
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis. One version of pediatric acute myeloid leukemia is the result of a reciprocal translocation between chromosomes 11 and X, with the breakpoint associated with the genes encoding the mixed-lineage leukemia and septin 2 proteins. This gene encodes four transcript variants encoding three distinct isoforms. An additional transcript variant has been identified, but its biological validity has not been determined.

Anti-Anti-SEPT9 Antibody antibody

STJ111369 100 µl
EUR 332.4
Description: This gene is a member of the septin family involved in cytokinesis and cell cycle control. This gene is a candidate for the ovarian tumor suppressor gene. Mutations in this gene cause hereditary neuralgic amyotrophy, also known as neuritis with brachial predilection. A chromosomal translocation involving this gene on chromosome 17 and the MLL gene on chromosome 11 results in acute myelomonocytic leukemia. Multiple alternatively spliced transcript variants encoding different isoforms have been described.

Anti-Anti-SEPT11 Antibody antibody

STJ111530 100 µl
EUR 332.4

Anti-Anti-SEPT4 Antibody antibody

STJ112276 100 µl
EUR 332.4
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is highly expressed in brain and heart. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. One of the isoforms (known as ARTS) is distinct; it is localized to the mitochondria, and has a role in apoptosis and cancer.

Anti-Anti-MARCH9 Antibody antibody

STJ112609 100 µl
EUR 332.4

Anti-Anti-SEPT2 Antibody antibody

STJ25475 100 µl
EUR 332.4

Anti-Anti-SEPT5 Antibody antibody

STJ25477 100 µl
EUR 332.4
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced.

Anti-Anti-SEPT8 Antibody antibody

STJ25479 100 µl
EUR 332.4
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Anti-Anti-SEPT2 Antibody antibody

STJ28365 100 µl
EUR 332.4

Anti-Anti-SEPT7 Antibody antibody

STJ28963 100 µl
EUR 332.4
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19.

Anti-Anti-SEPT1 antibody antibody

STJ119580 100 µl
EUR 332.4
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis and the maintenance of cellular morphology. This gene encodes a protein that can form homo- and heterooligomeric filaments, and may contribute to the formation of neurofibrillary tangles in Alzheimer's disease. Alternatively spliced transcript variants have been found but the full-length nature of these variants has not been determined. [provided by RefSeq, Dec 2012]

Anti-Anti-SEPT12 Antibody antibody

STJ117759 100 µl
EUR 332.4
Description: This gene encodes a guanine-nucleotide binding protein and member of the septin family of cytoskeletal GTPases. Septins play important roles in cytokinesis, exocytosis, embryonic development, and membrane dynamics. Multiple transcript variants encoding different isoforms have been found for this gene.

Anti-Anti-MARCH6 Antibody antibody

STJ118549 100 µl
EUR 332.4

Anti-Anti-MARCH6 Antibody antibody

STJ118550 100 µl
EUR 332.4

Anti-Anti-MARCH7 Antibody antibody

STJ118752 100 µl
EUR 332.4

Anti-Anti-SEPT3 Antibody antibody

STJ118990 100 µl
EUR 332.4

Anti-Anti-SEPT11 Antibody antibody

STJ113941 100 µl
EUR 332.4

Anti-Anti-SEPT11 Antibody antibody

STJ114081 100 µl
EUR 332.4

Anti-Anti-SEPT5 Antibody antibody

STJ114819 100 µl
EUR 332.4
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced.

Anti-Anti-MARCH8 Antibody antibody

STJ114828 100 µl
EUR 332.4

Anti-Anti-SEPT7 Antibody antibody

STJ116214 100 µl
EUR 332.4
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19.

Anti-Anti-SEPT8 Antibody antibody

STJ117206 100 µl
EUR 332.4
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Anti-Anti-DDB1 Antibody

A00333 100uL
EUR 546
Description: Rabbit Polyclonal DDB1 Antibody. Validated in IP and tested in Human, Mouse.

Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) ELISA Kit

AEA465Hu-10x96wellstestplate 10x96-wells test plate
EUR 6777.36
Description: This is Competitive Enzyme-linked immunosorbent assay for Antibody Detection.detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in serum, plasma and other biological fluids.

Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) ELISA Kit

AEA465Hu-1x48wellstestplate 1x48-wells test plate
EUR 663.31
Description: This is Competitive Enzyme-linked immunosorbent assay for Antibody Detection.detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in serum, plasma and other biological fluids.

Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) ELISA Kit

AEA465Hu-1x96wellstestplate 1x96-wells test plate
EUR 896.16
Description: This is Competitive Enzyme-linked immunosorbent assay for Antibody Detection.detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in serum, plasma and other biological fluids.

Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) ELISA Kit

AEA465Hu-5x96wellstestplate 5x96-wells test plate
EUR 3672.72
Description: This is Competitive Enzyme-linked immunosorbent assay for Antibody Detection.detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in serum, plasma and other biological fluids.

Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) ELISA Kit

4-AEA465Hu
  • EUR 6837.60
  • EUR 3613.20
  • EUR 896.40
  • 10 plates of 96 wells
  • 5 plates of 96 wells
  • 1 plate of 96 wells
Description: Enzyme-linked immunosorbent assay based on the Competitive Inhibition method for detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in samples from serum, plasma and other biological fluids with no significant corss-reactivity with analogues from other species.

ELISA kit for Human Anti-AsAb (Anti-Anti-Sperm Antibody Antibody)

ELK8071 1 plate of 96 wells
EUR 518.4
Description: A competitive Inhibition ELISA kit for detection of Anti-Anti-Sperm Antibody Antibody from Human in samples from blood, serum, plasma, cell culture fluid and other biological fluids.

Anti-H4K20me1 Antibody

CI1005 100ul
EUR 589.2
Description: Rabbit Polyclonal H4K20me1 Antibody. Validated in ChIP, ChIP-qPCR, WB and tested in Human.

Anti-H4K20me3 Antibody

CI1011 100ul
EUR 589.2
Description: Rabbit Polyclonal H4K20me3 Antibody. Validated in ChIP, ChIP-qPCR, WB and tested in Human.

Anti-TIP5 Antibody

CI1016 100ul
EUR 589.2
Description: Rabbit Polyclonal TIP5 Antibody. Validated in ChIP, ChIP-qPCR, WB and tested in Human, Mouse.

Anti-H4K8ac Antibody

CI1021 100ul
EUR 589.2
Description: Rabbit Polyclonal H4K8ac Antibody. Validated in ChIP, ChIP-qPCR, WB and tested in Human.

Anti-MYH11 Antibody

CI1028 100ul
EUR 589.2
Description: Rabbit Polyclonal MYH11 Antibody. Validated in ChIP, ChIP-qPCR, ChIP-seq, IHC, WB and tested in Human.

Anti-Ski3 Antibody

CI1031 150ug/50ul
EUR 589.2
Description: Rabbit Polyclonal Ski3 Antibody. Validated in ChIP, ChIP-qPCR, IF, IHC, WB and tested in Human.

Anti-Ski8 Antibody

CI1032 150ug/60ul
EUR 589.2
Description: Rabbit Polyclonal Ski8 Antibody. Validated in ChIP, ChIP-qPCR, WB and tested in Drosophila, Human.

Anti-H4K5,8,12ac Antibody

CI1033 50ug/66ul
EUR 589.2
Description: Rabbit Polyclonal H4K5,8,12ac Antibody. Validated in ChIP, ChIP-qPCR, ChIP-seq, IF, IHC, WB and tested in Human, Mouse.

Anti-H4K5,8,12,16ac Antibody

CI1035 50ug/66ul
EUR 589.2
Description: Rabbit Polyclonal H4K5,8,12,16ac Antibody. Validated in ChIP, ChIP-qPCR, ChIP-seq, IF, IHC, WB and tested in Human, Mouse.

Anti-H4K5ac Antibody

CI1036 50ug/28ul
EUR 589.2
Description: Rabbit Polyclonal H4K5ac Antibody. Validated in ChIP, ChIP-qPCR, ChIP-seq, IHC, WB and tested in Human, Mouse.

Anti-H4K20me1 Antibody

CI1039 50ug/25ul
EUR 589.2
Description: Rabbit Polyclonal H4K20me1 Antibody. Validated in ChIP, ChIP-qPCR, WB and tested in Human.

Anti-MeCP2 Antibody

CI1047 50ug/42ul
EUR 589.2
Description: Rabbit Polyclonal MeCP2 Antibody. Validated in ChIP, ChIP-qPCR, WB and tested in Human.

Anti-H4K20me3 Antibody

CI1050 50ug/47ul
EUR 589.2
Description: Rabbit Polyclonal H4K20me3 Antibody. Validated in ChIP, ChIP-qPCR, ChIP-seq, Flow Cytometry, IF, IHC, WB and tested in Human, Mouse.

Anti-H3K27me3 Antibody

CI1056 50ug/34ul
EUR 589.2
Description: Rabbit Polyclonal H3K27me3 Antibody. Validated in ChIP, ChIP-qPCR, ChIP-seq, IF, IHC, WB and tested in Arabidopsis, Drosophila, Human, Mouse, Rat, Schistosoma, Zebrafish.

Anti-MBD1 Antibody

CI1058 50ug/72ul
EUR 589.2
Description: Rabbit Polyclonal MBD1 Antibody. Validated in ChIP, ChIP-qPCR, Flow Cytometry, WB and tested in Human, Mouse.

Anti-p53 Antibody

CI1060 50ug/50ul
EUR 589.2
Description: Rabbit Polyclonal p53 Antibody. Validated in ChIP, ChIP-qPCR, ChIP-seq, Flow Cytometry, IHC, WB and tested in Human.

Anti-H4K8ac Antibody

CI1066 50ug/41ul
EUR 589.2
Description: Rabbit Polyclonal H4K8ac Antibody. Validated in ChIP, ChIP-qPCR, Flow Cytometry, IF, IHC, WB and tested in Human, Mouse.

Anti-H4pan Antibody

CI1069 50ug/44ul
EUR 589.2
Description: Rabbit Polyclonal H4pan Antibody. Validated in ChIP, ChIP-qPCR, Flow Cytometry, WB and tested in Human.

Anti-H2AK5ac Antibody

CI1078 50ug/ 54ul
EUR 589.2
Description: Rabbit Polyclonal H2AK5ac Antibody. Validated in ChIP, ChIP-qPCR, ChIP-seq, IHC, WB and tested in Human.

Antibody Anti-cKit

CKITACPO 0,1 mg
EUR 379.8

anti- LIN28B antibody

FNab04785 100µg
EUR 658.5
Description: Antibody raised against LIN28B

anti- LIN41 antibody

FNab04787 100µg
EUR 658.5
Description: Antibody raised against LIN41

anti- LIN7A antibody

FNab04788 100µg
EUR 702
Description: Antibody raised against LIN7A

anti- LIN7B antibody

FNab04789 100µg
EUR 658.5
Description: Antibody raised against LIN7B

anti- LIN7C antibody

FNab04790 100µg
EUR 658.5
Description: Antibody raised against LIN7C

anti- LIN9 antibody

FNab04791 100µg
EUR 606.3
Description: Antibody raised against LIN9

anti- LINGO1 antibody

FNab04792 100µg
EUR 658.5
Description: Antibody raised against LINGO1

anti- LIPA antibody

FNab04793 100µg
EUR 606.3
Description: Antibody raised against LIPA

anti- LIPC antibody

FNab04794 100µg
EUR 606.3
Description: Antibody raised against LIPC

anti- LIPH antibody

FNab04795 100µg
EUR 606.3
Description: Antibody raised against LIPH

anti- LIPI antibody

FNab04796 100µg
EUR 702
Description: Antibody raised against LIPI

anti- LITAF antibody

FNab04798 100µg
EUR 606.3
Description: Antibody raised against LITAF

anti- LKB1 antibody

FNab04802 100µg
EUR 658.5
Description: Antibody raised against LKB1

anti- LMAN1 antibody

FNab04803 100µg
EUR 658.5
Description: Antibody raised against LMAN1

anti- LMBR1L antibody

FNab04804 100µg
EUR 658.5
Description: Antibody raised against LMBR1L

anti- LMF1 antibody

FNab04805 100µg
EUR 606.3
Description: Antibody raised against LMF1

anti- LMF2 antibody

FNab04806 100µg
EUR 606.3
Description: Antibody raised against LMF2

anti- LMNB2 antibody

FNab04807 100µg
EUR 606.3
Description: Antibody raised against LMNB2

anti- LMOD1 antibody

FNab04808 100µg
EUR 606.3
Description: Antibody raised against LMOD1

anti- LMOD3 antibody

FNab04809 100µg
EUR 658.5
Description: Antibody raised against LMOD3

anti- LMP2 antibody

FNab04810 100µg
EUR 606.3
Description: Antibody raised against LMP2

anti- LMP7 antibody

FNab04811 100µg
EUR 658.5
Description: Antibody raised against LMP7

anti- LMX1B antibody

FNab04812 100µg
EUR 606.3
Description: Antibody raised against LMX1B

anti- LNPEP antibody

FNab04813 100µg
EUR 702
Description: Antibody raised against LNPEP

anti- LNX1 antibody

FNab04814 100µg
EUR 658.5
Description: Antibody raised against LNX1

anti- LOC123688 antibody

FNab04815 100µg
EUR 658.5
Description: Antibody raised against LOC123688

anti- LOC286135 antibody

FNab04816 100µg
EUR 658.5
Description: Antibody raised against LOC286135

anti- LOC55908 antibody

FNab04817 100µg
EUR 702
Description: Antibody raised against LOC55908

anti- LOC84740 antibody

FNab04818 100µg
EUR 702
Description: Antibody raised against LOC84740

anti- LOH12CR1 antibody

FNab04819 100µg
EUR 606.3
Description: Antibody raised against LOH12CR1

anti- LONP1 antibody

FNab04820 100µg
EUR 606.3
Description: Antibody raised against LONP1

anti- LONP1 antibody

FNab04821 100µg
EUR 702
Description: Antibody raised against LONP1

anti- Loricrin antibody

FNab04822 100µg
EUR 702
Description: Antibody raised against Loricrin

anti- LOX antibody

FNab04823 100µg
EUR 658.5
Description: Antibody raised against LOX

anti- LPAR4 antibody

FNab04824 100µg
EUR 606.3
Description: Antibody raised against LPAR4

anti- LPCAT1 antibody

FNab04825 100µg
EUR 658.5
Description: Antibody raised against LPCAT1

anti- LPCAT1 antibody

FNab04826 100µg
EUR 702
Description: Antibody raised against LPCAT1

anti- LPCAT2 antibody

FNab04827 100µg
EUR 658.5
Description: Antibody raised against LPCAT2

anti- LPCAT4 antibody

FNab04828 100µg
EUR 606.3
Description: Antibody raised against LPCAT4

anti- LPHN3 antibody

FNab04829 100µg
EUR 606.3
Description: Antibody raised against LPHN3

anti- LPIN2 antibody

FNab04830 100µg
EUR 702
Description: Antibody raised against LPIN2

anti- LPL antibody

FNab04831 100µg
EUR 606.3
Description: Antibody raised against LPL

anti- LPO antibody

FNab04834 100µg
EUR 658.5
Description: Antibody raised against LPO

anti- LPP antibody

FNab04835 100µg
EUR 702
Description: Antibody raised against LPP

anti- LPPR2 antibody

FNab04836 100µg
EUR 702
Description: Antibody raised against LPPR2

anti- LPXN antibody

FNab04837 100µg
EUR 606.3
Description: Antibody raised against LPXN

anti- LRAT antibody

FNab04838 100µg
EUR 606.3
Description: Antibody raised against LRAT

anti- LRCH1 antibody

FNab04839 100µg
EUR 702
Description: Antibody raised against LRCH1

anti- LRCH2 antibody

FNab04840 100µg
EUR 658.5
Description: Antibody raised against LRCH2

anti- LRCH3 antibody

FNab04841 100µg
EUR 606.3
Description: Antibody raised against LRCH3

anti- LRDD antibody

FNab04842 100µg
EUR 606.3
Description: Antibody raised against LRDD

anti- LRG1 antibody

FNab04843 100µg
EUR 702
Description: Antibody raised against LRG1

anti- LRMP antibody

FNab04844 100µg
EUR 702
Description: Antibody raised against LRMP

anti- LRMP antibody

FNab04845 100µg
EUR 702
Description: Antibody raised against LRMP

anti- LRP2BP antibody

FNab04846 100µg
EUR 606.3
Description: Antibody raised against LRP2BP

anti- LRP5 antibody

FNab04848 100µg
EUR 702
Description: Antibody raised against LRP5

anti- LRPAP1 antibody

FNab04849 100µg
EUR 702
Description: Antibody raised against LRPAP1

anti- LRPPRC antibody

FNab04850 100µg
EUR 606.3
Description: Antibody raised against LRPPRC

anti- LRRC1 antibody

FNab04852 100µg
EUR 658.5
Description: Antibody raised against LRRC1

anti- LRRC10 antibody

FNab04853 100µg
EUR 658.5
Description: Antibody raised against LRRC10

anti- LRRC18 antibody

FNab04854 100µg
EUR 658.5
Description: Antibody raised against LRRC18

anti- LRRC20 antibody

FNab04855 100µg
EUR 658.5
Description: Antibody raised against LRRC20

anti- LRRC29 antibody

FNab04856 100µg
EUR 702
Description: Antibody raised against LRRC29

anti- LRRC41 antibody

FNab04857 100µg
EUR 606.3
Description: Antibody raised against LRRC41

anti- LRRC47 antibody

FNab04858 100µg
EUR 658.5
Description: Antibody raised against LRRC47

anti- LRRC4C antibody

FNab04859 100µg
EUR 658.5
Description: Antibody raised against LRRC4C

anti- LRRC52 antibody

FNab04860 100µg
EUR 658.5
Description: Antibody raised against LRRC52

anti- LRRC8C antibody

FNab04861 100µg
EUR 606.3
Description: Antibody raised against LRRC8C

anti- LRRC8D antibody

FNab04862 100µg
EUR 606.3
Description: Antibody raised against LRRC8D

anti- LRRTM1 antibody

FNab04863 100µg
EUR 606.3
Description: Antibody raised against LRRTM1

anti- LRRTM2 antibody

FNab04864 100µg
EUR 658.5
Description: Antibody raised against LRRTM2

anti- LRRTM4 antibody

FNab04865 100µg
EUR 658.5
Description: Antibody raised against LRRTM4

anti- LRSAM1 antibody

FNab04866 100µg
EUR 658.5
Description: Antibody raised against LRSAM1

anti- LRWD1 antibody

FNab04867 100µg
EUR 702
Description: Antibody raised against LRWD1

anti- LSAMP antibody

FNab04868 100µg
EUR 658.5
Description: Antibody raised against LSAMP

anti- LSG1 antibody

FNab04869 100µg
EUR 658.5
Description: Antibody raised against LSG1

anti- LSM1 antibody

FNab04870 100µg
EUR 606.3
Description: Antibody raised against LSM1

anti- LSM10 antibody

FNab04871 100µg
EUR 658.5
Description: Antibody raised against LSM10

anti- LSM11 antibody

FNab04872 100µg
EUR 702
Description: Antibody raised against LSM11

anti- LSM14A antibody

FNab04873 100µg
EUR 658.5
Description: Antibody raised against LSM14A

anti- LSM2 antibody

FNab04874 100µg
EUR 606.3
Description: Antibody raised against LSM2

anti- LSM4 antibody

FNab04875 100µg
EUR 658.5
Description: Antibody raised against LSM4

anti- LSM5 antibody

FNab04876 100µg
EUR 702
Description: Antibody raised against LSM5

anti- LSM7 antibody

FNab04877 100µg
EUR 606.3
Description: Antibody raised against LSM7

anti- LSM8 antibody

FNab04878 100µg
EUR 606.3
Description: Antibody raised against LSM8

anti- LSP1 antibody

FNab04879 100µg
EUR 702
Description: Antibody raised against LSP1

anti- LSR antibody

FNab04880 100µg
EUR 606.3
Description: Antibody raised against LSR

anti- LSS antibody

FNab04881 100µg
EUR 606.3
Description: Antibody raised against LSS

anti- LSS antibody

FNab04882 100µg
EUR 606.3
Description: Antibody raised against LSS

anti- LTA4H antibody

FNab04883 100µg
EUR 606.3
Description: Antibody raised against LTA4H

anti- LTB4R antibody

FNab04884 100µg
EUR 702
Description: Antibody raised against LTB4R

anti- LTBP1 antibody

FNab04885 100µg
EUR 606.3
Description: Antibody raised against LTBP1

anti- LTBP2 antibody

FNab04886 100µg
EUR 606.3
Description: Antibody raised against LTBP2

anti- LTBR antibody

FNab04887 100µg
EUR 658.5
Description: Antibody raised against LTBR

anti- LUC7L antibody

FNab04888 100µg
EUR 606.3
Description: Antibody raised against LUC7L

anti- LUC7L2 antibody

FNab04889 100µg
EUR 702
Description: Antibody raised against LUC7L2

anti- Lumican antibody

FNab04890 100µg
EUR 606.3
Description: Antibody raised against Lumican

anti- LUZP1 antibody

FNab04891 100µg
EUR 658.5
Description: Antibody raised against LUZP1

anti- LXN antibody

FNab04893 100µg
EUR 606.3
Description: Antibody raised against LXN

anti- LY6D antibody

FNab04894 100µg
EUR 658.5
Description: Antibody raised against LY6D

anti- LY6E antibody

FNab04895 100µg
EUR 702
Description: Antibody raised against LY6E

anti- LY6G5B antibody

FNab04896 100µg
EUR 702
Description: Antibody raised against LY6G5B

anti- LY6G5C antibody

FNab04897 100µg
EUR 702
Description: Antibody raised against LY6G5C

anti- LY6G6F antibody

FNab04898 100µg
EUR 702
Description: Antibody raised against LY6G6F

anti- LY6K antibody

FNab04899 100µg
EUR 702
Description: Antibody raised against LY6K

anti- LY96 antibody

FNab04900 100µg
EUR 702
Description: Antibody raised against LY96

anti- LYAR antibody

FNab04901 100µg
EUR 702
Description: Antibody raised against LYAR

anti- LYN antibody

FNab04903 100µg
EUR 702
Description: Antibody raised against LYN

anti- LYN antibody

FNab04904 100µg
EUR 658.5
Description: Antibody raised against LYN

Switching b/tsDMARDs could also be a proxy for increased illness severity or poorly managed RA and an vital confounder to contemplate in acquiring unbiased estimates of VTE danger in observational RA security research.

Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting.
Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting.

Cardiovascular danger of synthetic, non-biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs).

Patients with rheumatoid ailments have an elevated danger of CVD and CVD-related dying in contrast with the basic inhabitants. Both the conventional cardiovascular danger elements and systemic irritation are contributors to this phenomenon. This evaluate examines the obtainable proof about the results of synthetic, non-biologic disease-modifying antirheumatic drugs (DMARDs) in CVD danger.

This is a crucial situation for clinicians when deciding on particular person remedy plans in patients with rheumatic ailments. Evidence means that synthetic, non-biologic DMARDs similar to methotrexate, sulfosalazine, hydroxychloroquine, leflunomide and tofacitinib present decreased CVD morbidity and mortality. However, the strongest knowledge in favor of a discount in CVD occasions in rheumatoid patients are proven with methotrexate which has been the focus of most research.

Adequate proof for a beneficial impact additionally exists for hydroxychlorokine. Larger, potential research and randomized scientific trials are wanted to raised characterize the impact of synthetic, non-biologic DMARDs on CVD outcomes in these patients.

Design of future research ought to embody areas with lack of proof, similar to the danger for coronary heart failure, arrhythmias and valvular coronary heart illness. The clinically related query whether or not synthetic, non-biologic DMARDs are inferior to biologic DMARDs in phrases of CVD outcomes nonetheless stays not adequately addressed.

Leave a Comment

Your email address will not be published.

Scroll to Top